Nature Communications (Jul 2017)
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer
- Manav Korpal,
- Xiaoling Puyang,
- Zhenhua Jeremy Wu,
- Roland Seiler,
- Craig Furman,
- Htoo Zarni Oo,
- Michael Seiler,
- Sean Irwin,
- Vanitha Subramanian,
- Jaya Julie Joshi,
- Chris K. Wang,
- Victoria Rimkunas,
- Davide Tortora,
- Hua Yang,
- Namita Kumar,
- Galina Kuznetsov,
- Mark Matijevic,
- Jesse Chow,
- Pavan Kumar,
- Jian Zou,
- Jacob Feala,
- Laura Corson,
- Ryan Henry,
- Anand Selvaraj,
- Allison Davis,
- Kristjan Bloudoff,
- James Douglas,
- Bernhard Kiss,
- Morgan Roberts,
- Ladan Fazli,
- Peter C. Black,
- Peter Fekkes,
- Peter G. Smith,
- Markus Warmuth,
- Lihua Yu,
- Ming-Hong Hao,
- Nicholas Larsen,
- Mads Daugaard,
- Ping Zhu
Affiliations
- Manav Korpal
- H3 Biomedicine Inc.
- Xiaoling Puyang
- H3 Biomedicine Inc.
- Zhenhua Jeremy Wu
- H3 Biomedicine Inc.
- Roland Seiler
- Department of Urologic Sciences, University of British Columbia
- Craig Furman
- H3 Biomedicine Inc.
- Htoo Zarni Oo
- Department of Urologic Sciences, University of British Columbia
- Michael Seiler
- H3 Biomedicine Inc.
- Sean Irwin
- H3 Biomedicine Inc.
- Vanitha Subramanian
- H3 Biomedicine Inc.
- Jaya Julie Joshi
- H3 Biomedicine Inc.
- Chris K. Wang
- Department of Urologic Sciences, University of British Columbia
- Victoria Rimkunas
- H3 Biomedicine Inc.
- Davide Tortora
- Department of Urologic Sciences, University of British Columbia
- Hua Yang
- Eisai Inc., 4 Corporate Drive
- Namita Kumar
- Eisai Inc., 4 Corporate Drive
- Galina Kuznetsov
- Eisai Inc., 4 Corporate Drive
- Mark Matijevic
- Eisai Inc., 4 Corporate Drive
- Jesse Chow
- Eisai Inc., 4 Corporate Drive
- Pavan Kumar
- H3 Biomedicine Inc.
- Jian Zou
- H3 Biomedicine Inc.
- Jacob Feala
- H3 Biomedicine Inc.
- Laura Corson
- H3 Biomedicine Inc.
- Ryan Henry
- H3 Biomedicine Inc.
- Anand Selvaraj
- H3 Biomedicine Inc.
- Allison Davis
- H3 Biomedicine Inc.
- Kristjan Bloudoff
- H3 Biomedicine Inc.
- James Douglas
- Department of Urology, University Hospital of Southampton
- Bernhard Kiss
- Department of Urology, University of Bern
- Morgan Roberts
- Department of Urologic Sciences, University of British Columbia
- Ladan Fazli
- Department of Urologic Sciences, University of British Columbia
- Peter C. Black
- Department of Urologic Sciences, University of British Columbia
- Peter Fekkes
- H3 Biomedicine Inc.
- Peter G. Smith
- H3 Biomedicine Inc.
- Markus Warmuth
- H3 Biomedicine Inc.
- Lihua Yu
- H3 Biomedicine Inc.
- Ming-Hong Hao
- H3 Biomedicine Inc.
- Nicholas Larsen
- H3 Biomedicine Inc.
- Mads Daugaard
- Department of Urologic Sciences, University of British Columbia
- Ping Zhu
- H3 Biomedicine Inc.
- DOI
- https://doi.org/10.1038/s41467-017-00147-w
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Muscle-invasive bladder cancer (MIBC) is a potentially lethal disease. Here the authors characterize diverse genetic alterations in MIBC that convergently lead to constitutive activation of PPARgamma/RXRalpha and result in immunosurveillance escape by inhibiting CD8+ T-cell recruitment.
